• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals (‘AFT’) has reached agreement with privately-owned Swiss headquartered multinational pharmaceutical company, Acino Pharma AG (‘Acino’), to out-license the product line of its patented combination painkiller, Maxigesic, to a further 69 countries.

    To view the announcements please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Share Price & Graph

-0.05 -1.6%
9:08AM 22/10/2016
0.00 0.0%
4:00PM 19/10/2016
View more



Key Dates

Financial Half Year End 30/09/2016
Annual Shareholders Meeting 05/08/2016
FY2016 Full Year Results Announcement 25/05/2016
Financial Year End 31/03/2016

Latest Investor

View our latest presentations

Sign up for a request to be invited onto
our email subscribers database.